EPIGRAL vs NOCIL: Stock Comparison

Epigral Limited vs NOCIL Limited

Live data: 24 July 2026, 4:08 PM IST • Source: NSE and company filings

Epigral Limited is the larger company by market capitalisation. Epigral Limited shows a lower P/E, a higher ROE and faster revenue growth, while NOCIL Limited shows a higher dividend yield and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Epigral Limited and NOCIL Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, EPIGRAL is more favourable on 10 of 13 scored metrics and NOCIL on 3These counts are context-free and are not an overall rating.

Key Differences

Market Cap
EPIGRAL is the larger company
₹5,036 Cr vs ₹2,680 Cr
P/E Ratio
EPIGRAL has a lower P/E
15.04x vs 48.56x
P/B Ratio
NOCIL has a lower P/B
1.52x vs 2.25x
EPS
EPIGRAL has higher earnings per share
₹75.27 vs ₹3.32
Dividend Yield
NOCIL has a higher dividend yield
1.12% vs 0.43%
Revenue Growth (TTM YoY)
EPIGRAL has faster revenue growth
17.3% vs -2.8%
EPS Growth (TTM YoY)
EPIGRAL has faster EPS growth
-6.8% vs -19.2%
Qtr Sales Growth
EPIGRAL has stronger quarterly sales growth
17.3% vs -2.75%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricEPIGRALNOCIL
SectorChemicalsChemicals
IndustrySpecialty ChemicalsSpecialty Chemicals

Price

MetricEPIGRALNOCIL
Live Price₹1,162.7₹160.11
Day Change0.93%-1.23%
Volume3.02 L3.33 L
52-Week High₹2,114₹204.5
52-Week Low₹807₹125.31
Distance from 52W High-45%-21.71%

Valuation

MetricEPIGRALNOCIL
Market Cap₹5,036 Cr₹2,680 Cr
P/E Ratio15.04x48.56x
P/B Ratio2.25x1.52x
EPS₹75.27₹3.32
Book Value₹514.92₹106.4
Dividend Yield0.43%1.12%

Growth

MetricEPIGRALNOCIL
Revenue Growth (TTM YoY)17.3%-2.8%
EPS Growth (TTM YoY)-6.8%-19.2%
Qtr Sales Growth17.3%-2.75%
Qtr Profit Growth-6.84%-18.2%

Profitability & Leverage

MetricEPIGRALNOCIL
ROE16%2.6%
ROCE15.5%3.93%
Net Margin13.14%4.86%
Operating Margin22.4%7.73%
Debt to Equity0.26x0x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricEPIGRALNOCIL
Promoter Holding68.83%33.76%
FII Holding1.03% 0.51 pp4.78% 0.23 pp
DII Holding5.56% 0.66 pp7.47% 0.44 pp
Public Holding24.55% 0.15 pp53.98% 0.2 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Epigral Limited and NOCIL Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.